For the Inventor, By the Inventor

Enter assignee name

Dublin, Ireland

Inflazome Limited

USPTO Granted Patents = 20

EPO Patents = 3

Forward Citations = 10

Loading Chart...

Loading Chart...

19 inventors (with patents filed for the assignee):

David Miller (19 out of 28 patents)

Jonathan Shannon (15 out of 22 patents)

Matthew Cooper (15 out of 27 patents)

4. Angus Macleod (13 out of 13 patents)

5. Stephen St-Gallay (12 out of 12 patents)

6. Stephen Thom (12 out of 60 patents)

7. Jimmy Van Wiltenburg (11 out of 12 patents)

8. Thomas Alanine (3 out of 3 patents)

9. Ian Strutt (3 out of 5 patents)

10. Jokin Carrillo Arregui (3 out of 3 patents)

11. Stuart Thomas Onions (2 out of 67 patents)

12. Jochem Theodoor Van Herpt (2 out of 3 patents)

13. Susana Del Rio Gancedo (1 out of 9 patents)

14. Samuel Stratford (1 out of 7 patents)

15. Paul Leeson (1 out of 1 patent)

20 patents: Sort by Forward Citations

1. 12221434 - Sulfonamide carboxamide compounds (2025-02-11),

2. 12187702 - Sulfonamideurea compounds (2025-01-07),

3. 12168653 - Sulfonamide derivates as NLRP3 inhibitors (2024-12-17),

4. 12030879 - Sulfonyl acetamides as NLRP3 inhibitors (2024-07-09),

5. 12012392 - Sulfonamide carboxamide compounds (2024-06-18),

6. 11981667 - Sulfonamide carboxamide compounds (2024-05-14),

7. 11926600 - Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors (2024-03-12),

8. 11905252 - Compounds (2024-02-20),

9. 11884645 - Sulfonyl acetamides as NLRP3 inhibitors (2024-01-30),

10. 11834433 - Compounds (2023-12-05),

11. 11773058 - Sulfonamide carboxamide compounds (2023-10-03),

12. 11724988 - Processes (2023-08-15),

13. 11623922 - Compounds (2023-04-11),

14. 11613542 - Sulfonylureas and sulfonylthioureas as NLRPinhibitors (2023-03-28),

15. 11542255 - Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors (2023-01-03),

Inflazome Limited is a biotechnology company based in Dublin, Ireland, specializing in the development of innovative therapeutics targeting inflammatory diseases. The company focuses on harnessing its expertise in pharmacology and biochemistry to create novel small molecule inhibitors that modulate the immune response. By addressing the underlying mechanisms of inflammation, Inflazome aims to provide effective treatments for conditions such as neurodegeneration and autoimmune disorders, contributing to advancements in precision medicine.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

20 Patents

#67 in Dublin

#114 in Ireland

#31,196 in the World

Dublin, Ireland

Inflazome Limited

Forward Citations = 10

19 inventors:

David Miller (19 out of 28 patents)

Jonathan Shannon (15 out of 22 patents)

Matthew Cooper (15 out of 27 patents)

4. Angus Macleod (13 out of 13 patents)

5. Stephen St-Gallay (12 out of 12 patents)

Please report any incorrect information to [email protected]

Loading…